NCT07080242View on ClinicalTrials.gov

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Small-cell Lung CancerNeuroendocrine CancerProstate CancerGastrointestinal Neuroendocrine TumorMerkel Cell Carcinoma, Recurrent
Interventions
DRUG

BL-M14D1

BL-M14D1 will be administered on D1 every 3 weeks.

Trial Locations (3)

22031

NOT_YET_RECRUITING

NEXT Oncology Virginia, Fairfax

90067

NOT_YET_RECRUITING

Valkyrie Clinical Trials, Los Angeles

07601

RECRUITING

John Theurer Cancer Center-Hackensack, Hackensack

All Listed Sponsors
lead

SystImmune Inc.

INDUSTRY

NCT07080242 - Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter